| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/00365540410019039 |
| P698 | PubMed publication ID | 15061660 |
| P2093 | author name string | Johan S Bakken | |
| P2860 | cites work | Emerging mechanisms of fluoroquinolone resistance | Q24644842 |
| Structure-activity and structure-side-effect relationships for the quinolone antibacterials | Q28246405 | ||
| Maintaining fluoroquinolone class efficacy: review of influencing factors | Q30310427 | ||
| Expanded activity and utility of the new fluoroquinolones: a review | Q33544588 | ||
| Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group | Q33926761 | ||
| Minimizing quinolone resistance: are the new agents more or less likely to cause resistance? | Q33933067 | ||
| Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. | Q33981343 | ||
| Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniae | Q33982417 | ||
| Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. | Q34107785 | ||
| Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. | Q34177418 | ||
| Roles of topoisomerase IV and DNA gyrase in DNA unlinking during replication in Escherichia coli | Q34297971 | ||
| Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States | Q34347889 | ||
| Fluoroquinolones: action and resistance | Q35061150 | ||
| Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections | Q35111896 | ||
| Prokaryotic DNA replication | Q35671078 | ||
| Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients | Q35814807 | ||
| Quinolone-binding pocket of DNA gyrase: role of GyrB. | Q39652111 | ||
| Bactericidal activities of five quinolones for Escherichia coli strains with mutations in genes encoding the SOS response or cell division | Q39871693 | ||
| Mechanisms of high-level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa | Q40285759 | ||
| Repair of DNA double-strand breaks in Escherichia coli, which requires recA function and the presence of a duplicate genome | Q40840136 | ||
| From chloroquine to antineoplastic drugs? the story of antibacterial quinolones. | Q41327203 | ||
| Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials | Q42671287 | ||
| Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae | Q42852778 | ||
| Fluoroquinolone pharmacodynamics | Q43801621 | ||
| Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia | Q43908420 | ||
| Changing use of antibiotics in community-based outpatient practice, 1991-1999. | Q44384152 | ||
| Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). | Q44396648 | ||
| Gatifloxacin, Gemifloxacin, and Moxifloxacin: The Role of 3 Newer Fluoroquinolones | Q44616842 | ||
| Serum Bactericidal Activity of the Methoxyfluoroquinolones Gatifloxacin and Moxifloxacin against Clinical Isolates of Staphylococcus Species: Are the Susceptibility Breakpoints Too High? | Q44635725 | ||
| Widespread use of fluoroquinolones versus emerging resistance in pneumococci | Q46142425 | ||
| Multidrug resistance--a sign of the times | Q50131238 | ||
| Conformational changes in DNA gyrase revealed by limited proteolysis. | Q53947449 | ||
| Integration of molecular characterization of microorganisms in a global antimicrobial resistance surveillance program. | Q54011822 | ||
| DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage. | Q54588445 | ||
| Hydrolysis of ATP at Only One GyrB Subunit Is Sufficient to Promote Supercoiling by DNA Gyrase | Q57980006 | ||
| The future of fluoroquinolones | Q58173254 | ||
| Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents | Q71403126 | ||
| AUIC--the universal parameter within the constraint of a reasonable dosing interval | Q71697436 | ||
| Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America | Q74315684 | ||
| Mechanisms of fluoroquinolone resistance | Q74371163 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 85-92 | |
| P577 | publication date | 2004-01-01 | |
| P1433 | published in | Infectious Diseases | Q7429961 |
| P1476 | title | The fluoroquinolones: how long will their utility last? | |
| P478 | volume | 36 |
| Q48175293 | A 5-kg time-resolved luminescence photometer with multiple excitation sources. |
| Q24613844 | Antibiotic prophylaxis for urinary tract infections after removal of urinary catheter: meta-analysis |
| Q91792950 | Antimicrobial agents for preventing urinary tract infections in adults undergoing cystoscopy |
| Q26470640 | Antimicrobial agents for preventing urinary tract infections in patients undergoing cystoscopy |
| Q36171292 | Community-acquired antibiotic resistance in urinary isolates from adult women in Canada |
| Q40493675 | Disposition kinetics and dosage regimen of levofloxacin on concomitant administration with paracetamol in crossbred calves |
| Q36939682 | Fluoroquinolone prescriptions in a teaching hospital: a prospective audit |
| Q36526009 | Heavy use of prophylactic antibiotics in aquaculture: a growing problem for human and animal health and for the environment |
| Q39900661 | Pharmacokinetics, urinary excretion and dosage regimen of levofloxacin following a single intramuscular administration in cross bred calves |
| Q79712920 | Plasma concentrations, pharmacokinetics and urinary excretion of gatifloxacin after single intravenous injection in buffalo calves |
| Q38097417 | Plasmid-mediated quinolone resistance--current knowledge and future perspectives |
| Q36353529 | Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies |
| Q37018238 | The management of acute uncomplicated cystitis in adult women by family physicians in Canada |
Search more.